[Immunosuppression and induction of tolerance by 3-(2-chloroethyl)-2(2-mesyloxyethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (ASTA 5122)].
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003498:Cyclic P-Oxides / Q000494:pharmacology* / Q000633:toxicity; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006087:Graft vs Host Reaction / Q000187:drug effects; D006384:Hemagglutination / Q000187:drug effects; D006462:Hemolytic Plaque Technique; D007108:Immune Tolerance / Q000187:drug effects*; D007165:Immunosuppression Therapy / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007928:Lethal Dose 50; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008214:Lymphocytes / Q000187:drug effects; D008698:Mesylates / Q000494:pharmacology / Q000633:toxicity; D051379:Mice; D010078:Oxazines / Q000494:pharmacology*; D013154:Spleen / Q000276:immunology
D000970:Antineoplastic Agents; D003498:Cyclic P-Oxides; D007166:Immunosuppressive Agents; D008698:Mesylates; D010078:Oxazines
Immunsuppression und Toleranzinduktion durch 3-(2-Chloräthyl)-2(2-mesyloxyäthyl-amino)-tetrahydro-2H-1,3,2,-oxazaphosphorin-2-oxid (ASTA 5122)